US govt seeks new trial in Gilead HIV drug patent case

The government lost its high stakes and unusual royalties dispute with the big pharma firm | New status report claims that the court should have allowed the jury to take four inter partes petitions into account.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Big Pharma

Gilead and Teva prevail in $3.6bn antitrust trial

4 July 2023 Verdict confirms legality of 2014 patent settlement, dismissing allegations of anti competitive practices.

Big Pharma

Trial set for Gilead HIV antitrust claims case

23 February 2023 Gilead, Johnson & Johnson and others will face trial in May | Class-action suit involves allegations of anticompetitive practices.

Americas

Gilead hit with antitrust suit over HIV drugs

16 January 2020 Gilead and its alleged co-conspirators Bristol-Myers Squibb, Japan Tobacco, and Johnson & Johnson have been accused of engaging in a long-running scheme to suppress competition in the market for HIV prevention therapies.

More features

Trade secrets go global: How brand owners face a high-stakes battlefront

Killing the golden goose of US drug innovation (Part II): Drug pricing myths

Former pharma GC brings in-house perspective to McGuireWoods

Sandoz eyes US biosimilar launch as Regeneron settles

Killing the golden goose of US drug innovation (Part I): Follow the money

Buchalter brings in new partner to head up medtech

Trump’s march-in rights threat: Why pharma is rethinking collaborations

UK gets new IP minister following cabinet reshuffle

US govt seeks new trial in Gilead HIV drug patent case

More on this story

Editor's picks

Editor's picks

More features